BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

BerGenBio AS 

Thormohlensgt 51, 5006

  Bergen    Norway
Phone: 47-535-01-564 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






 Company News
BerGenBio AS Presents Positive Phase Ia Data On BGB324 At American Association for Cancer Research 4/9/2014 11:09:17 AM    More...
BerGenBio AS Wraps Up $12.5 Million Funding Round 2/5/2014 5:34:39 AM    More...
BerGenBio AS Presents Data At American Association for Cancer Research-ISLAC Conference On The Molecular Origins Of Lung Cancer 1/9/2014 10:34:31 AM    More...
BerGenBio AS Release: Data Highlights BGB324 As A Potential Novel Treatment Option For Drug Resistant Chronic Myeloid Leukemia 12/17/2013 9:37:31 AM    More...
BerGenBio AS Release: Study Published in Blood Highlights Axl Inhibition as a Novel Therapeutic Approach for Acute Myeloid Leukemia 10/1/2013 8:54:43 AM    More...
BerGenBio AS Study Published in Blood Highlights Axl Inhibition as a Novel Therapeutic Approach for Acute Myeloid Leukemia 9/30/2013 9:15:12 AM    More...
BerGenBio AS Announces Initiation of Phase I Clinical Trial for First-in-Class AXL Receptor Tyrosine Kinase Inhibitor BGB324 to Treat Aggressive and Metastatic Cancers 6/20/2013 9:10:45 AM    More...
BerGenBio AS Presents Promising Therapeutic Candidate in AML at American Society of Clinical Oncology 6/3/2013 7:16:56 AM    More...
BerGenBio AS Secures Additional $6 Million as First in Class AXL Kinase Inhibitor BGB324 Approaches Clinic 5/31/2013 10:24:23 AM    More...
BerGenBio AS Selects Sygnature Discovery for BGB002 Drug Development 10/8/2012 11:27:58 AM    More...
12

//-->